Pathological findings in central nervous system demyelination associated with infliximab

Alicja Kalinowska-Lyszczarz; Mahboobeh Fereidan-Esfahani; Yong Guo; Claudia F. Lucchinetti; W. Oliver Tobin

doi:10.1177/1352458519894710

Pathological findings in central nervous system demyelination associated with infliximab

Alicja Kalinowska-Lyszczarz, Mahboobeh Fereidan-Esfahani, Yong Guo, Claudia F. Lucchinetti, W. Oliver Tobin

Neurology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.

Original language	English (US)
Pages (from-to)	1124-1129
Number of pages	6
Journal	Multiple Sclerosis Journal
Volume	26
Issue number	9
DOIs	https://doi.org/10.1177/1352458519894710
State	Published - Aug 1 2020

Keywords

Demyelination
central nervous system
infliximab
multiple sclerosis
neuropathology
rheumatoid arthritis
tumor necrosis factor (TNF) alpha inhibitors

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1177/1352458519894710

Cite this

@article{51465dce664c47819ef1363a70f54802,

title = "Pathological findings in central nervous system demyelination associated with infliximab",

abstract = "Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.",

keywords = "Demyelination, central nervous system, infliximab, multiple sclerosis, neuropathology, rheumatoid arthritis, tumor necrosis factor (TNF) alpha inhibitors",

author = "Alicja Kalinowska-Lyszczarz and Mahboobeh Fereidan-Esfahani and Yong Guo and Lucchinetti, {Claudia F.} and Tobin, {W. Oliver}",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2019.",

year = "2020",

month = aug,

day = "1",

doi = "10.1177/1352458519894710",

language = "English (US)",

volume = "26",

pages = "1124--1129",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "9",

}

TY - JOUR

T1 - Pathological findings in central nervous system demyelination associated with infliximab

AU - Kalinowska-Lyszczarz, Alicja

AU - Fereidan-Esfahani, Mahboobeh

AU - Guo, Yong

AU - Lucchinetti, Claudia F.

AU - Tobin, W. Oliver

N1 - Publisher Copyright: © The Author(s), 2019.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.

AB - Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.

KW - Demyelination

KW - central nervous system

KW - infliximab

KW - multiple sclerosis

KW - neuropathology

KW - rheumatoid arthritis

KW - tumor necrosis factor (TNF) alpha inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85077379821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077379821&partnerID=8YFLogxK

U2 - 10.1177/1352458519894710

DO - 10.1177/1352458519894710

M3 - Article

C2 - 31845616

AN - SCOPUS:85077379821

SN - 1352-4585

VL - 26

SP - 1124

EP - 1129

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 9

ER -

Pathological findings in central nervous system demyelination associated with infliximab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this